¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dark field objective"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • objective structured clinical examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • objective symptom
    °´°üÁõ»ó, Ÿ°¢Áõ»ó
  • objective tinnitus
    Ÿ°¢±Í¿ï¸², Ÿ°¢À̸í
  • objective vertigo
    Ÿ°¢Çö±âÁõ
  • auditory field
    û°¢¹üÀ§, û¿ª
  • altitudinal visual field defect
    ¼öÆò½Ã¾ß°á¼Õ
  • abutted field
    ÀÎÁ¢Á¶»ç¸é, Á¢ÃËÁ¶»ç¸é
  • B1 field gradient
    ȸÀüÀÚÀå±â¿ï±â
  • binocular field
    ¾ç¾È½Ã¾ß, µÎ´«½Ã¾ß
  • boost field
    Á¶»ç¿µ¿ª, Á¶»ç¸é
  • complex receptive field
    º¹ÇÕ¼ö¿ë¾ß
  • comprehensive field irradiation
    ±¤¹üÀ§Á¶»ç
  • congruous field defect
    ÀÏÄ¡½Ã¾ß°á¼Õ
  • diplopia field
    º¹½Ã½Ã¾ß, °ãº¸Àӽþß
  • electric field
    Àü±âÀå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • objective symptom
    Ÿ°¢Áõ»ó
  • objective tinnitus
    Ÿ°¢±Í¿ï¸², Ÿ°¢À̸í
  • objective vertigo
    Ÿ°¢Çö±â, ÁÖÀ§¾îÁö·³
  • objective hearing test
    Ÿ°¢Ã»·Â°Ë»ç, °´°üÀûû·Â°Ë»ç
  • abutted field
    ÀÎÁ¢Á¶»ç¸é, Á¢ÃËÁ¶»ç¸é
  • altitudinal visual field defect
    ¼öÆò½Ã¾ß°á¼Õ
  • auditory field
    û°¢¹üÀ§, û¿ª
  • geometric field distortion artifact
    ±âÇÏÇÐÀûÀÚÀå¿Ö°îÀΰø¹°
  • B1 field gradient
    ȸÀüÀÚÀå±â¿ï±â
  • binocular field
    ¾ç¾È½Ã¾ß, µÎ´«½Ã¾ß
  • boost field
    Á¶»ç¿µ¿ª, Á¶»ç¸é
  • field block
    ºÎÀ§Â÷´Ü¸¶Ãë
  • complex receptive field
    º¹ÇÕ¼ö¿ë¾ß
  • comprehensive field irradiation
    ±¤¹üÀ§Á¶»ç
  • confrontation field test
    ´ë¸é½Ã¾ß°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gravitational field
    Áß·ÂÀå(ñìæ³íÞ).
  • high field MR scanner
    °íÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • point outside field
    Á¶»ç¿µ¿ª¹ÛÁöÁ¡
  • pulsed-field gel electrophoresis (PFGE)
    °£Çæ¾ß Àü±â¿µµ¿
  • radio-frequency field
    °íÁÖÆÄ ÀÚÀå
  • rectangular field of view (FOV)
    Á÷»ç°¢Çü ½Ã¾ß
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hearing test, objective
    °´°üÀû û·Â°Ë»ç, Ÿ°¢Àû û·Â°Ë
  • lens, objective
    ´ë¹°·»Áî
  • objective
    ´ë»ó(ÓßßÚ), ¸ñÀû¹°(ÙÍîÜÚª), °´°üÀû(ËÔκîÜ), Ÿ°¢Àû(öâÊÆîÜ), ´ë¹°(ÓßÚª)·»Áî.
  • objective
    ´ë»ó
  • objective audiometry
    Ÿ°¢(Àû) û·ÂÃøÁ¤(¹ý)
  • objective hearing test
    Ÿ°¢(Àû) û·Â°Ë»ç, °´°üÀû û·Â
  • objective lens
    ´ë¹°(ÓßÚª)·»Áî.
  • objective micrometer
    ´ë¹°(ÓßÚª)¸¶ÀÌÅ©·Î¹ÌÅÍ.
  • objective micrometer
    ´ë¹°(ÓßÚª)¸¶ÀÌÅ©·Î¹ÌÅÍ
  • objective photometry
    °´°üÀû Ãø±¤¹ý(ËÔκîÜö´ÎÃÛö).
  • objective sensation
    °´°üÀû °¨°¢.
  • objective sensory physiology
    °´°üÀû °¨°¢ »ý¸®ÇÐ
  • objective sign
    Ÿ°¢Àû ¡ÈÄ(öâÊÆîÜó£ý¦).
  • objective symptom
    Ÿ°¢Áõ»ó(öâÊÆñøßÒ).
  • objective tinnitus
    Ÿ°¢(Àû) À̸í
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear electric field effect
    ¼±Çü Àü±âÀåÈ¿°ú(àÊû¡ï³Ñ¨íÞüùÍý)
  • magnetic field
    ÀÚÀå(í¸íÞ)
  • pulsed-field gel electrophoresis
    ÆÞ½ºÀå(íÞ) Á© Àü±â¿µµ¿(ï³Ñ¨ç¶ÔÑ)
  • sedimentation field flow fractionation
    ħ°­Àå(öØË½íÞ) È帧ºÐȹ¹ý(ÝÂüñÛö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • field inhomogeneity
    ÀÚÀåºÒ±ÕÀÏ(¼º)
  • field of view [=FOV]
    ¿µ»ó¿µ¿ª, ¿µ»ó¹üÀ§
  • field profile
    ÀÚÀåÃø¸é»ó
  • field size
    Á¶»ç¾ßÅ©±â
  • field strength
    ÀÚÀå¼¼±â, ÀÚÀå·Â
  • field survey
    ÇöÁöÁ¶»ç
  • FOV [=field of view]
    ¿µ»ó¿µ¿ª, ¿µ»ó¹üÀ§
  • fringe field
    ÁÖº¯¾ß
  • fringe magnetic field strength
    ÁÖº¯ÀÚÀå¼¼±â
  • geometric field distortion artifact
    ±âÇÏÇÐÀûÀÚÀå¿Ö°îÀΰø¹°
  • gradient magnetic field
    °æ»çÀÚ±âÀå
  • high field MR scanner
    °íÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • horizontal field magnet
    ¼öÆò¸éÀÚ¼®
  • in-field-of-view saturation band
    ¿µ»ó¿µ¿ª³»Æ÷È­´ë
  • intermediate field MR scanner
    ÁßµîÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
BO Bachelor of Osteopathy; base of prism out; behavior objective; belladonna and opium; body odor; bowe...
MBO management by objective; mesiobucco-occlusal
OB obese [mouse]; obese, obesity; objective benefit; obliterative bronchiolitis; obstetrics, obstetrici...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
D Dark
DA Dark Agouti
DR Dark-reared
LD Light-dark
LD 12:12 light-dark cycle
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dark spot
    £Àº ¹ÝÁ¡
  • dark-adaptation test
    ¾Ï¼øÀÀ ½ÃÇè
  • absolute field
    Àý´ë ºÎ
    ´ë³úÀÇ ÀϺηÎ, ±× º´º¯¿¡ ÀÇÇØ °æ·Ã ¶Ç´Â ¸¶ºñ¸¦ ÀÏÀ¸Å²´Ù.
  • abutted field
    ÀÎÁ¢ Á¶»ç¸é
  • bright field photomicrograph
    ?
  • color field
    »ö ½Ã¾ß
  • constant field equation
    Á¤ÀüÀå ¹æÁ¤½Ä
  • cortical field
    ÇÇÁú ¿µ¿ª
  • depository field
    ÷°¡ ¾ß
  • electromagnetic field
    ÀüÀÚÀå
    1. Àü±âÀå°ú ÀÚ±âÀåÀ» ÅëÆ²¾î ÁöĪÇÏ´Â ¸». 2. Àü±âÀå°ú ÀÚ±âÀåÀÌ ¼­·Î ¿¬°üµÇ¾î °°ÀÌ ³ªÅ¸³¯ ¶§ À̸£´Â ¸».
  • equivalent field
    µî°¡ Á¶»ç ¿µ¿ª
  • eye field
    ½Ã¾ß
  • far field
    ¿ø°Å¸® ±¸¿ª
  • field
    ±¸¿ª, ¾ß, ¿µ¿ª
    1. ÀÛ¿ë ¿µ¿ª ¶Ç´Â Àå¼Ò³ª °ø°£. 2. Áö½Ä, ¿¬±¸, Á÷¾÷¿¡ À־ÀÇ Àü¹® ºÐ¾ß. 3. ¹ß»ýÇп¡ ÀÖ¾î º¯µ¿ ¿äÀÎÀÇ ¹üÀ§ ³»¿¡¼­ ºÐÈ­ÇÏ´Â ¿µ¿ª.
  • field cancerization
    ±¸¿ª ¾ÏÈ­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
dark reaction <biochemistry, plant biology> The reactions in photosynthesis that occur after NADPH and ATP production and that take place in the stroma of the chloroplast.
By means of the reaction, carbon dioxide is incorporated into carbohydrate.
(18 Nov 1997)
dark t2 lesion <radiology> (short T2), acute haemorrhage (deoxyHb), haemosiderin, physiologic iron (basal ganglia, etc.), mucinous lesions (?) most abnormalities have long T1 and T2 (dark/bright).
Compare: bright T1 lesion.
(07 Mar 2000)
achromatic objective <microscopy> An objective that is corrected chromatic for two colours, and spherically for one, usually in the yellow-green part of the spectrum.
(05 Aug 1998)
apochromatic objective <microscopy> A lens system whose secondary chromatic aberrations have been substantially reduced.
It is designed to provide the same focal length for three wavelengths and freedom from spherical aberration for two wavelengths of light. The magnification can still vary with wavelength in which case a compensating eyepieces used to cancel the coloured fringes.
(05 Aug 1998)
plan apochromatic objective lens <physics> A modern, high-numerical aperture microscope objective lens designed with high degrees of corrections for various aberrations. It is corrected for spherical aberration in four wavelengths (dark blue, blue, green, and red), for chromatic aberration in more than these four wavelengths, and for flatness of field. A single Plan Apo objective may contain as many as 11 lens elements.
(05 Aug 1998)
homogeneous immersion objective <microscopy> An objective to be immersed in a liquid of a certain refractive index and dispersion value as specified by the manufacturer of the objective. An oil-immersion objective, the most important type, is intended to be immersed in cedarwood oil (nD = 1.515) or in its manmade optical equivalent. A water-immersion objective is for dipping into an aqueous specimen mount. Alpha-monobromonaphthalene has such a high refractive index (nD = 1.66) that a very highly resolving objective (1.60 numerical aperture) was designed to be immersed in that liquid, for use by reflected light on metals and other opaque objects.
(05 Aug 1998)
semi-apochromatic objective <microscopy> A compromise, in the correction for chromatic and spherical aberration, between achromatic and apochromatic objectives, such as a fluorite objective.
(05 Aug 1998)
dry objective <microscopy> Any microscope objective designed for use without immersion liquids.
(05 Aug 1998)
immersion objective <microscopy> An objective in which the medium of high refractive index and is used in the object space to increase the numerical aperture and hence the resolving power of the lens.
See: homogeneous immersion of objective.
(05 Aug 1998)
objective 1. <psychology> Perceptible to the external senses.
2. <ophthalmology> The lens or system of lenses in a microscope (or telescope) that is nearest to the object under examination.
Origin: L. Objectivus
(18 Nov 1997)
objective assessment data Those facts presented by the client that show his/her perception, understanding and interpretation of what is happening.
(05 Mar 2000)
objective circle <microscopy> When the focused objective is examined by with- drawing the ocular and viewing its back focal plane through the microscope bodytube, the limiting boundary of the objective, the circumference of the white spot of light, is the objective circle.
(05 Aug 1998)
objective, fluorite <microscopy> An objective using the mineral fluorite in its construction. It is usually intermediate between achromatic and apochromatic in correction, but may be more highly corrected.
See: illumination, eyepiece.
(05 Aug 1998)
objective optometer <optics> A contrivance for exhibiting and measuring the refraction of light.
Origin: Refraction.
Source: Websters Dictionary
(01 Mar 1998)
objective perimetry Determination of the visual field by pupillary constriction, electroencephalography, or eye movements.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dark adaptation
    (»ý¸®)¾Ï¼øÀÀ
  • dark adapted
    (»ý¸®)¾Ï¼øÀÀÀÇ
  • dark brown star
    (õ)¾Ï°¥»öÀÇ º°(°¡½Ã±¤À» °ÅÀÇ ¹ßÇÏÁö ¾Ê´Â ÀºÇÏ ¼ÓÀÇ Àû¿Ü¼±¿ø X
  • dark comedy
    =BLOCK HUMOR,BLOCK COMEDY
  • dark days
    1ºÒ¿ìÇÑ ½Ã´ë;½½·³Çà ½Ã±â
  • dark deeda
    ºñÇà
  • dark horse
    ´Ùũȣ½º(°æ¸¶,¼±°Å µî¿¡¼­ ¿ª·® ¹ÌÁöÀÇ À¯·ÂÇÑ »ó´ë)
  • dark lantern
    ÃÊ·Õ;µî·Õ
  • dark meat
    ¿ä¸®ÇÏ¸é °Ë¾îÁö´Â °í±â(´ß´Ù¸® °í±â µî);(¹Ì)ÈæÀÎ ¿©ÀÚ
  • dark rays
    ¾Ïº¹»ç¼±(Àڿܼ±À̳ª Àû¿Ü¼± °°Àº ´«¿¡ º¸ÀÌÁö ¾Ê´Â ±¤¼±)
  • dark reaction
    (½Ä)¾Ï¹ÝÀÀ
  • field
    ÀüÅõ,ÅõÁö,½Î¿ì´Ù,´ÙÅõ´Ù
  • Field Marshal
    À°±º ¿ø¼ö
  • Field prize
    Çʵå»ó
  • brick field
    º®µ¹°øÀå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á